Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2019)
Vir Biotechnology (VIR) posted Gains from Investment Securities of -$1.4 million for Q4 2019, down 151.66% sequentially from $2.6 million in Q3 2019, and up 22.96% YoY from -$1.1 million in Q4 2018.
Powered by 
Analysis
Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2019) Analysis & Trends
Vir Biotechnology has reported Gains from Investment Securities for 2 years, with the latest figure at -$1.4 million in Q4 2019.
- Quarterly Gains from Investment Securities rose 22.96% year-over-year to -$1.4 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $2.0 million (changed N/A YoY) and the FY2023 annual result came in at $1.0 million, down 51.58% from the prior year.
- Gains from Investment Securities retreated to -$1.4 million in Q4 2019 per VIR's latest filing, from $2.6 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.6 million in Q3 2019 and troughed at -$1.8 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vir Biotechnology | 1.92 Bn | 1.92 Bn | 238.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 4.93 Mn |
| Sep 30, 2019 | 2.62 Mn |
| Jun 30, 2019 | 427,000.00 |
| Mar 31, 2019 | 357,000.00 |
| Dec 31, 2018 | 165,000.00 |